Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion |
| Therapy | JYP0322 |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion | lung non-small cell carcinoma | predicted - sensitive | JYP0322 | Phase I | Actionable | In a Phase I trial, JYP0322 treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring ROS1 fusions, resulting in an objective response rate (ORR) of 85.7% (12/14) in ROS1-TKI naive patients and an ORR of 54.5% (12/22) in patients treated with at least 2 lines of systemic therapy and 1 line of a ROS1-TKI (Cancer Res (2025) 85 (8_Supplement_2): CT052; NCT06128148). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT052: A highly selective, brain-penetrant and overcoming G2032R resistance ROS1 inhibitor JYP0322 in NSCLC patients with ROS1 fusion | Full reference... |